Product nameAnti-Chd7 antibody
See all Chd7 primary antibodies
DescriptionRabbit polyclonal to Chd7
Tested applicationsSuitable for: ICC, ICC/IF, WB, IHC-Pmore details
Species reactivityReacts with: Mouse, Human
An 18 amino acid synthetic peptide from near the N terminus of Human Chd7.
- SK-N-SH cell lysate
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
Storage bufferPreservative: 0.02% Sodium azide
Constituent: 99% PBS
Concentration information loading...
PurityImmunogen affinity purified
Purification notesab117522 was purified by affinity chromatography via a peptide column.
Our Abpromise guarantee covers the use of ab117522 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC||Use a concentration of 5 µg/ml.|
|ICC/IF||Use a concentration of 20 µg/ml.|
|WB||Use a concentration of 1 - 2 µg/ml. Predicted molecular weight: 336 kDa.|
|IHC-P||Use at an assay dependent concentration.|
FunctionProbable transcription regulator.
Tissue specificityWidely expressed in fetal and adult tissues.
Involvement in diseaseDefects in CHD7 are a cause of CHARGE syndrome (CHARGES) [MIM:214800]. This syndrome, which is a common cause of congenital anomalies, is characterized by a non-random pattern of congenital anomalies including choanal atresia and malformations of the heart, inner ear, and retina.
Genetic variations in CHD7 are associated with susceptibility to idiopathic scoliosis type 3 (IS3) [MIM:608765]. Idiopathic scoliosis (IS) is the most common spinal deformity in children.
Defects in CHD7 are the cause of Kallmann syndrome type 5 (KAL5) [MIM:612370]. Kallmann syndrome is a disorder that associates hypogonadotropic hypogonadism and anosmia. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In some patients other developmental anomalies can be present, which include renal agenesis, cleft lip and/or palate, selective tooth agenesis, and bimanual synkinesis. In some cases anosmia may be absent or inconspicuous.
Defects in CHD7 are a cause of idiopathic hypogonadotropic hypogonadism (IHH) [MIM:146110]. IHH is defined as a deficiency of the pituitary secretion of follicle-stimulating hormone and luteinizing hormone, which results in the impairment of pubertal maturation and of reproductive function.
Sequence similaritiesBelongs to the SNF2/RAD54 helicase family.
Contains 2 chromo domains.
Contains 1 helicase ATP-binding domain.
Contains 1 helicase C-terminal domain.
modificationsPhosphorylated upon DNA damage, probably by ATM or ATR.
- Information by UniProt
- ATP-dependent helicase CHD7 antibody
- ATP-dependent helicase chromodomain helicase DNA binding protein 7 antibody
- CHD-7 antibody
Lane 1 : Anti-Chd7 antibody (ab117522) at 1 µg/ml
Lane 2 : Anti-Chd7 antibody (ab117522) at 2 µg/ml
All lanes : SK-N-SH cell lysate
Lysates/proteins at 15 µg per lane.
Predicted band size: 336 kDa
Immunofluorescence of Chd7 in mouse brain tissue with ab117522 at 20 ug/mL.
Immunohistochemistry of CHD7 in mouse brain tissue with ab117522 at 5 ug/mL.
ab117522 has not yet been referenced specifically in any publications.